A 32-year-old woman with a family history of early-onset breast and ovarian cancer is found to carry a BRCA1 mutation. She is counseled regarding risk reduction strategies. Which drug is the preferred choice for chemoprevention in BRCA1 mutation carriers to reduce breast cancer risk?

Question

Accepted Answer

D. Tamoxifen. ## Chemoprevention in BRCA1 Mutation Carriers

**Key Point:** Tamoxifen is the gold-standard chemopreventive agent for BRCA1/BRCA2 mutation carriers at high risk of breast cancer, reducing incidence by approximately 50%.

### Mechanism of Action
Tamoxifen acts as a selective estrogen receptor modulator (SERM), blocking estrogen signaling in breast tissue while maintaining estrogenic effects in bone and cardiovascular tissue.

### Evidence Base
The NSABP P-1 trial demonstrated that tamoxifen reduces breast cancer risk in high-risk women, including BRCA carriers. It is FDA-approved for breast cancer prevention in women at high risk.

### Clinical Considerations

| Feature | Tamoxifen | Aromatase Inhibitors (Letrozole, Anastrozole) |
|---------|-----------|----------------------------------------------|
| **Mechanism** | SERM (ER antagonist in breast) | Blocks estrogen synthesis |
| **Efficacy in BRCA** | Proven (50% risk reduction) | Less evidence in BRCA carriers |
| **Menopausal status** | Both pre- and postmenopausal | Postmenopausal only |
| **Bone effects** | Protective | Detrimental |
| **VTE risk** | Increased | Lower |
| **Endometrial cancer** | Increased risk (~2×) | No increase |

**High-Yield:** Tamoxifen is the only chemopreventive agent with robust evidence in BRCA mutation carriers across both pre- and postmenopausal women.

**Clinical Pearl:** Aromatase inhibitors may be considered in postmenopausal BRCA carriers, but tamoxifen remains first-line due to superior evidence base and ability to use in premenopausal women.

**Warning:** Do not confuse chemoprevention with therapeutic treatment — aromatase inhibitors are used in treatment of established ER+ breast cancer but lack evidence for prevention in BRCA carriers.

Answer

A. Anastrozole

Answer

B. Fulvestrant

Answer

C. Letrozole

A 32-year-old woman with a family history of early-onset breast and ovarian cancer is found to carry a BRCA1 mutation. She is counseled regarding risk reduction strategies. Which drug is the preferred choice for chemoprevention in BRCA1 mutation carriers to reduce breast cancer risk?

Explanation

Chemoprevention in BRCA1 Mutation Carriers

Mechanism of Action

Evidence Base

Clinical Considerations

Practice similar questions

Join our NEET PG community

Feature	Tamoxifen	Aromatase Inhibitors (Letrozole, Anastrozole)
Mechanism	SERM (ER antagonist in breast)	Blocks estrogen synthesis
Efficacy in BRCA	Proven (50% risk reduction)	Less evidence in BRCA carriers
Menopausal status	Both pre- and postmenopausal	Postmenopausal only
Bone effects	Protective	Detrimental
VTE risk	Increased	Lower
Endometrial cancer	Increased risk (~2×)	No increase